4-Amino-Acid Peptide Homes to Brain Tumors and Delivers Chemotherapy More Effectively
The SIWV tetrapeptide derived from annexin-A3 specifically targets glioblastoma tissue and significantly improved drug delivery in a mouse brain tumor model.
Quick Facts
What This Study Found
The SIWV peptide was identified from an isoform of annexin-A3, a human membrane-interacting protein. It showed remarkable specificity for glioblastoma tissue both in cell cultures and in living mice.
The peptide enters cells through a caveolin-mediated endocytosis pathway, confirmed through receptor inhibition and genetic knockdown experiments.
When grafted onto porous silicon nanoparticles loaded with the cancer drug SN-38, SIWV-targeted nanoparticles showed significantly better tumor targeting than scrambled-peptide controls in a mouse brain tumor model. The treatment also showed statistically significant anti-tumor efficacy (P < 0.05) compared to free SN-38.
Key Numbers
4-amino-acid peptide (SIWV); P < 0.05 vs free SN-38; enhanced targeting vs scrambled control
How They Did This
This was a preclinical study using both cell cultures and a mouse xenograft model of glioblastoma. Researchers identified the SIWV sequence from annexin-A3, characterized its cell entry mechanism through inhibition studies, and tested therapeutic efficacy by loading porous silicon nanoparticles with SN-38 and grafting them with SIWV via a PEG linker.
Why This Research Matters
Glioblastoma is the most aggressive brain tumor, and getting drugs past the blood-brain barrier to reach these tumors is one of the biggest challenges in oncology. A peptide that specifically homes to glioblastoma tissue could dramatically improve drug delivery.
The fact that SIWV is only four amino acids long makes it relatively simple to manufacture and attach to various drug carriers.
The Bigger Picture
Glioblastoma is the most aggressive brain cancer with poor response to chemotherapy, largely because drugs cannot reach the tumor effectively. A simple 4-amino-acid homing peptide that crosses the blood-brain barrier and targets tumor tissue could transform drug delivery for brain cancers.
What This Study Doesn't Tell Us
This was tested in a mouse xenograft model, which uses human tumor cells implanted into immune-compromised mice. This does not fully replicate the human brain tumor environment or immune system.
The study did not test whether SIWV crosses the blood-brain barrier when tumors are intact, which is critical for clinical translation.
Questions This Raises
- ?Does SIWV cross the intact blood-brain barrier or only the disrupted barrier around tumors?
- ?Could SIWV be used to deliver other drugs or imaging agents to brain tumors?
- ?Would this work in immunocompetent mice with intact immune responses?
Trust & Context
- Key Stat:
- 4 amino acids the remarkably simple SIWV peptide specifically targets glioblastoma and improves chemotherapy delivery in a mouse model
- Evidence Grade:
- Preliminary evidence from a mouse xenograft model. Promising but immune-compromised mice may not reflect human treatment response.
- Study Age:
- Published in 2020. Brain tumor targeting peptides remain an active area of research.
- Original Title:
- A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma.
- Published In:
- Nanoscale horizons, 5(8), 1213-1225 (2020)
- Authors:
- Kang, Rae Hyung, Jang, Jeong-Eun, Huh, Eugene, Kang, Seong Jae, Ahn, Dae-Ro, Kang, Jae Seung, Sailor, Michael J, Yeo, Seung Geun, Oh, Myung Sook, Kim, Dokyoung, Kim, Hyo Young
- Database ID:
- RPEP-04894
Evidence Hierarchy
Frequently Asked Questions
Why is drug delivery to brain tumors so difficult?
The blood-brain barrier normally prevents drugs from reaching the brain. Even in brain tumors where the barrier is partially disrupted, drugs often cannot accumulate in sufficient concentrations. Tumor-homing peptides could guide drugs directly to the tumor.
Could a peptide this small really be effective?
Its simplicity is actually an advantage. Small peptides are cheap to manufacture, easy to conjugate to drugs, and may penetrate tissues more effectively than larger molecules. The key is its specificity for tumor tissue.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04894APA
Kang, Rae Hyung; Jang, Jeong-Eun; Huh, Eugene; Kang, Seong Jae; Ahn, Dae-Ro; Kang, Jae Seung; Sailor, Michael J; Yeo, Seung Geun; Oh, Myung Sook; Kim, Dokyoung; Kim, Hyo Young. (2020). A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma.. Nanoscale horizons, 5(8), 1213-1225. https://doi.org/10.1039/d0nh00077a
MLA
Kang, Rae Hyung, et al. "A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma.." Nanoscale horizons, 2020. https://doi.org/10.1039/d0nh00077a
RethinkPeptides
RethinkPeptides Research Database. "A brain tumor-homing tetra-peptide delivers a nano-therapeut..." RPEP-04894. Retrieved from https://rethinkpeptides.com/research/kang-2020-a-brain-tumorhoming-tetrapeptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.